Search research articles
Contact Us
Filters
Showing results (401-410 of 418) with videos related to
Page
of 42
Sort By:
Nature Communications
|
July 25, 2022
Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ
Qian Zhou, Wan-Wan Sun, Jia-Cong Chen, et al.
Theranostics
|
January 16, 2020
Smooth muscle SIRT1 reprograms endothelial cells to suppress angiogenesis after ischemia
Yong-Qing Dou, Peng Kong, Chang-Lin Li, et al.
Protein & Cell
|
January 3, 2024
Follicle stimulating hormone controls granulosa cell glutamine synthesis to regulate ovulation
Kai-Hui Zhang, Fei-Fei Zhang, Zhi-Ling Zhang, et al.
Cell Reports. Medicine
|
March 7, 2026
Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer
Tingting Zhang, Wangpeng Cui, Haitao Tang, et al.
The Lancet. Respiratory Medicine
|
May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
Clinical and Experimental Rheumatology
|
December 11, 2019
Validation of new classification criteria of rheumatoid arthritis in an international multicentre study
Ru Li, Xing Sun, Hua Ye, et al.
Cell Reports
|
March 16, 2022
Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake
Song-Hua Hu, Xia-Di He, Ji Nie, et al.
The Lancet Regional Health. Western Pacific
|
September 16, 2021
Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region
Xing Sun, Ru Li, Yueming Cai, et al.
The Lancet. Oncology
|
July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
Cancer Cell
|
June 28, 2024
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Page
of 42
Search research articles
Search
Showing results (401-410 of 418) with videos related to
Sort By:
Page
of 42
Nature Communications
|
July 25, 2022
Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ
Qian Zhou, Wan-Wan Sun, Jia-Cong Chen, et al.
Theranostics
|
January 16, 2020
Smooth muscle SIRT1 reprograms endothelial cells to suppress angiogenesis after ischemia
Yong-Qing Dou, Peng Kong, Chang-Lin Li, et al.
Protein & Cell
|
January 3, 2024
Follicle stimulating hormone controls granulosa cell glutamine synthesis to regulate ovulation
Kai-Hui Zhang, Fei-Fei Zhang, Zhi-Ling Zhang, et al.
Cell Reports. Medicine
|
March 7, 2026
Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer
Tingting Zhang, Wangpeng Cui, Haitao Tang, et al.
The Lancet. Respiratory Medicine
|
May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
Clinical and Experimental Rheumatology
|
December 11, 2019
Validation of new classification criteria of rheumatoid arthritis in an international multicentre study
Ru Li, Xing Sun, Hua Ye, et al.
Cell Reports
|
March 16, 2022
Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake
Song-Hua Hu, Xia-Di He, Ji Nie, et al.
The Lancet Regional Health. Western Pacific
|
September 16, 2021
Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region
Xing Sun, Ru Li, Yueming Cai, et al.
The Lancet. Oncology
|
July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lu, Lin Wu, Hong Jian, et al.
Cancer Cell
|
June 28, 2024
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Page
of 42